Impact BioMedical (IBO) Q2 2026 earnings summary

Executive summary

• Focused on developing and licensing proprietary healthcare and wellness technologies, with ongoing efforts to monetize intellectual property and control costs.

• Principal subsidiaries include Global BioLife, Impact BioLife Science, Global BioMedical, and Sweet Sense.

• Key technologies in development: Linebacker (oncology/inflammation), Laetose (metabolic health), 3F (functional fragrances), and Equivir (antiviral supplement).

Financial highlights

• Revenue for Q2 2026 was $3,000, down 57% year-over-year; six-month revenue was $10,000, up 43% from prior year.

• Net loss for Q2 2026 was $700,000, a 95% improvement year-over-year; six-month net loss was $2,983,000, down 81%.

• Total assets as of June 30, 2026 were $16.7 million, with $10,000 in cash and $16.4 million in intangible assets.

• Stock-based compensation for the six months ended June 30, 2026 was $1,440,000.

Outlook and guidance

• Management is exploring capital raises and debt financing to address going concern risks.

• Plans include monetizing intellectual property and tightly controlling operating costs.